FDA cites increased death risk in decision to yank approval for TG Therapeutics cancer drug
Following previously revealed safety concerns, the FDA on Wednesday said it has withdrawn TG Therapeutics’ cancer drug Ukoniq to treat two specific types of lymphoma, marginal zone lymphoma and follicular lymphoma.
The decision comes as updated findings from an ongoing trial of the drug, known generically as umbralisib, show an increased risk of death in patients, and FDA said the risks of treatment with Ukoniq outweigh its benefits.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.